Exomic Sequencing of Medullary Thyroid Cancer Reveals Dominant and Mutually Exclusive Oncogenic Mutations in RET and RAS
The Journal of Clinical Endocrinology & Metabolism2012Vol. 98(2), pp. E364–E369
Citations Over TimeTop 1% of 2012 papers
Nishant Agrawal, Yuchen Jiao, Mark Sausen, Rebecca Leary, Chetan Bettegowda, Nicholas J. Roberts, Sheetal Bhan, Allen S. Ho, Zubair Khan, Justin A. Bishop, William H. Westra, Laura D. Wood, Ralph H. Hruban, Ralph P. Tufano, Bruce Robinson, Henning Dralle, S. P. A. Toledo, Rodrigo A. Toledo, Luc G.T. Morris, Ronald Ghossein, James A. Fagin, Timothy A. Chan, Victor E. Velculescu, Bert Vogelstein, Kenneth W. Kinzler, Nickolas Papadopoulos, Barry D. Nelkin, Douglas W. Ball
Abstract
Approximately 90% of MTCs had mutually exclusive mutations in RET, HRAS, and KRAS, suggesting that RET and RAS are the predominant driver pathways in MTC. Relatively few mutations overall and no commonly recurrent driver mutations other than RET, HRAS, and KRAS were seen in the MTC exome.
Related Papers
- → Drugging All RAS Isoforms With One Pocket(2020)73 cited
- → Multiplexed screens identify RAS paralogues HRAS and NRAS as suppressors of KRAS-driven lung cancer growth(2023)31 cited
- → Targeting the KRAS α4-α5 allosteric interface inhibits pancreatic cancer tumorigenesis(2021)15 cited
- → Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy(2023)5 cited
- → Clinical significance of HRAS and KRAS genes expression in patients with non–small-cell lung cancer.(2020)